Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study
Alimentary Pharmacology & Therapeutics · 2025-08 · 62 (3) · 330-339
DOI: 10.1111/apt.70189 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2025-05-28. Written by J Tack and 20 co-authors. Institution: Rome Foundation Research Institute, Raleigh, North Carolina, USA. Major MEDLINE topics: Dyspepsia. Cited 39 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Functional dyspepsia (FD) is one of the most common disorders of gut–brain interaction (DGBI). Varying reported population prevalences probably reflect different definitions and methodological approaches.
Aim
To study the prevalence and impact of FD and its subgroups in an internet survey.
Methods
A total of 54,127 respondents from 26 countries completed the survey including the Rome IV diagnostic questionnaire, Patient Health Questionnaire‐4 (PHQ‐4), PHQ‐12, PROMIS Global‐10, demographics, and medical history. Respondents reporting a history of relevant organic disease, or fulfilling criteria for self‐induced or cyclic vomiting, or cannabinoid hyperemesis were excluded.
Results
Rome IV FD prevalence was 7.2% (range 2.2%–12.3%), significantly higher in women and decreased with age. The most prominent subtype was postprandial distress syndrome (PDS) (66.6%). Rome IV IBS was found in 26.1% of those fulfilling FD criteria. Functional heartburn and chronic nausea and vomiting criteria were fulfilled in, respectively, 9.0% and 7.0%. Fulfilling FD symptom criteria was significantly associated with increased prevalence of anxiety and depression and with lower quality of life and higher healthcare seeking behaviour.
Conclusions
Rome IV FD is one of the most prevalent DGBI globally. Across countries, it is associated with female sex, younger age, psychological distress, reduced quality of life, and higher health care utilisation. PDS is the dominant subgroup. Overlapping other DGBI are present in a minority.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Rome Foundation Research Institute, Raleigh, North Carolina, USA.
- Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Belgium.
- Gastroenterology-Hepatology Division, Leuven University Hospitals, Leuven, Belgium.
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
- Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
ORCID profiles: B Broeders, X Fang, S Fukudo, U C Ghoshal, E M Quigley, W E Whitehead, A D Sperber
Cite
APA
Tack, J., Palsson, O. S., Bangdiwala, S. I., Schol, J., Carbone, F., Van Den Houte, K., Broeders, B., Drossman, D., Dumitrascu, D. L., Fang, X., Fukudo, S., Ghoshal, U. C., Kellow, J., Khatun, R., Okeke, E., Quigley, E. M., Schmulson, M., Simrén, M., Whitehead, W. E., …, & Sperber, A. D. (2025). Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study. Alimentary Pharmacology & Therapeutics, 62(3), 330-339. https://doi.org/10.1111/apt.70189
Vancouver
Tack J, Palsson OS, Bangdiwala SI, Schol J, Carbone F, Van Den Houte K, et al. Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study. Alimentary Pharmacology & Therapeutics. 2025;62(3):330-339. doi:10.1111/apt.70189
BibTeX
@article{Tack2025,
author = {Tack, J and Palsson, O S and Bangdiwala, S I and Schol, J and Carbone, F and Van Den Houte, K and Broeders, B and Drossman, D and Dumitrascu, D L and Fang, X and Fukudo, S and Ghoshal, U C and Kellow, J and Khatun, R and Okeke, E and Quigley, E M and Schmulson, M and Simrén, M and Whitehead, W E and Whorwell, P and Sperber, A D},
title = {Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {3},
pages = {330--339},
doi = {10.1111/apt.70189}
}
EUVIMED